Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Age and smoking predict antibody titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine

Yushi Nomura, Michiru Sawahata, Yosikazu Nakamura, Momoko Kurihara, Ryousuke Koike, Otohiro Katsube, Koichi Hagiwara, Seiji Niho, Norihiro Masuda, Takaaki Tanaka, Kumiya Sugiyama
doi: https://doi.org/10.1101/2021.08.06.21261590
Yushi Nomura
1Department of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital
2Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michiru Sawahata
1Department of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital
3Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sawahata@jichi.ac.jp
Yosikazu Nakamura
4Department of Public Health, Jichi Medical University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Momoko Kurihara
1Department of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryousuke Koike
1Department of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital
2Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Otohiro Katsube
1Department of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koichi Hagiwara
3Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seiji Niho
2Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norihiro Masuda
5Department of Surgery, National Hospital Organization Utsunomiya National Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takaaki Tanaka
6Department of Orthopaedic Surgery, National Hospital Organization Utsunomiya National Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kumiya Sugiyama
1Department of Respiratory Medicine and Clinical Immunology, National Hospital Organization Utsunomiya National Hospital
7Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Objective We aimed to determine antibody (Ab) titres 3 months after the second dose of the BNT162b2 coronavirus disease-2019 (COVID-19) vaccine and to explore clinical variables predicting these titres in Japan.

Methods We enrolled 378 healthcare workers (255 women, 123 men) whose blood samples were collected 91±15 days after the second of two inoculations of the BNT162b2 COVID-19 mRNA vaccine (Pfizer/BioNTech) given 3 weeks apart. Medical histories and demographic characteristics were recorded using a structured self-reported questionnaire. The relationships between Ab titres and these factors were analysed.

Results Median age (interquartile range [IQR]) of the participants was 44 (32-54) years. Median Ab titre (IQR) against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antigen was 764 (423-1140) U/mL. Older participants had significantly lower Ab titres; median (IQR) Ab titres were 942 (675-1390) and 1095 (741-1613) U/mL in men and women in their 20s, respectively, but 490 (297-571) and 519 (285-761) U/mL in men and women in their 60s-70s, respectively. In the age-adjusted analysis, the only risk factors for lower Ab titres were male sex and smoking. However, the sex difference may have arisen from the sex difference in smoking rate. Moreover, Ab titres were significantly lower in current smokers than in ex-smokers.

Conclusion The most important factors associated with low Ab titres were age and smoking habit. In particular, current smoking status caused lower Ab titres, and smoking cessation before vaccination may improve the individual efficacy of the BNT162b2 vaccine.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No fundings.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Ethics Committee of National Hospital Organization Utsunomiya National Hospital (No. 03-01, April 19, 2021).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data referred to in the manuscript are available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 07, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Age and smoking predict antibody titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Age and smoking predict antibody titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine
Yushi Nomura, Michiru Sawahata, Yosikazu Nakamura, Momoko Kurihara, Ryousuke Koike, Otohiro Katsube, Koichi Hagiwara, Seiji Niho, Norihiro Masuda, Takaaki Tanaka, Kumiya Sugiyama
medRxiv 2021.08.06.21261590; doi: https://doi.org/10.1101/2021.08.06.21261590
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Age and smoking predict antibody titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine
Yushi Nomura, Michiru Sawahata, Yosikazu Nakamura, Momoko Kurihara, Ryousuke Koike, Otohiro Katsube, Koichi Hagiwara, Seiji Niho, Norihiro Masuda, Takaaki Tanaka, Kumiya Sugiyama
medRxiv 2021.08.06.21261590; doi: https://doi.org/10.1101/2021.08.06.21261590

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (553)
  • Anesthesia (135)
  • Cardiovascular Medicine (1761)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (660)
  • Epidemiology (10803)
  • Forensic Medicine (8)
  • Gastroenterology (593)
  • Genetic and Genomic Medicine (2953)
  • Geriatric Medicine (287)
  • Health Economics (534)
  • Health Informatics (1930)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (631)
  • Infectious Diseases (except HIV/AIDS) (12520)
  • Intensive Care and Critical Care Medicine (693)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2801)
  • Nursing (151)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1469)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (867)
  • Pharmacology and Therapeutics (366)
  • Primary Care Research (338)
  • Psychiatry and Clinical Psychology (2641)
  • Public and Global Health (5374)
  • Radiology and Imaging (1014)
  • Rehabilitation Medicine and Physical Therapy (596)
  • Respiratory Medicine (726)
  • Rheumatology (330)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (150)
  • Urology (126)